Rose Bengal (PV-10) in treating melanoma, breast cancer, liver cancer and cancers metastatic to the liver

Rose Bengal is a dye with various uses. Its salt compound occurs in eye drops commonly used to identify damage after eye injuries. It has also long been used to diagnose brucellosis, a disease transmitted through direct animal contact or unpasteurized milk and dairy products. It is used as a textile dye too. Beyond these established applications, Rose Bengal has been tested in cancer treatment over the past few years.
Initially, injecting Rose Bengal into affected areas in malignant melanoma, an aggressive skin cancer, achieved %75 disease control. Subsequent testing in other cancers produced positive results particularly in breast and liver cancers.
Its injectable formulation is being studied as PV-10. PV-10 is designed for injection directly into tumors (intralesional administration). At the European 17th gastrointestinal congress (ESMO 17th World Congress on Gastrointestinal Cancer [ESMO-GI]), early results from 230 cancer patients were presented. This attracted considerable attention as the first study demonstrating PV-10 effectiveness beyond melanoma.
Among participants, 13 patients have been followed after a single intratumoral PV-10 dose for 40 months without signs of worsening. Of these, 6 had hepatocellular liver cancer; the others had colorectal, lung, melanoma or ovarian cancer metastatic to the liver.
Another study presented last October involving stage-3 melanoma in 28 patients found that PV-10 injected into cancerous lesions produced complete response, disappearance of the tumor, in half.
Rose Bengal is thought to exert anticancer effects by activating lysosomal enzymes in cancer cells and indirectly activating the immune system. Its effects have been shown not to remain localized but also to be systemic. Tumor shrinkage at noninjected sites and increased circulating immune cells after injection are cited as evidence.
In conclusion, Although cancer research involving Rose Bengal has attracted limited interest so far, it is among the most intriguing topics of recent years. We eagerly await large-scale results from ongoing studies.
Sources
Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver.
Poster Number: P-116, ESMO 17th World Congress on Gastrointestinal Cancer
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.